Top Markets
#1 ADO Protocol ADO Protocol +329.72%
#2 GoPlus Security GoPlus Security +51.65%
#3 Nockchain Nockchain +47.38%
#4 Tutorial Tutorial +42.31%
#5 Starpower Starpower +33.22%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +30.91%
#7 The Black Bull The Black Bull +27.75%
#8 GAIB AID GAIB AID +24.67%
#9 Casper Network Casper Network +17.77%
#10 Verus Coin Verus Coin +16.89%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
NightHawk Biosciences, Inc. NightHawk Biosciences, Inc.

NightHawk Biosciences, Inc.

NHWK
Rank in Stocks #33282
NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm,... NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm, dedicated to advancing immune therapies and vaccines. Their core mission involves leveraging and modifying the body's immune system to combat a range of illnesses, particularly various cancers and infectious diseases. Central to their strategy is the proprietary gp96 platform. This platform encompasses two key technologies: ImPACT, an allogeneic (off-the-shelf) cell-based system designed to activate and expand T-cells, acting as a broad immune stimulant; and ComPACT, which combines antigen-specific T-cell activation with targeted co-stimulation in a single product. NightHawk's clinical pipeline features several promising candidates: HS-110, which has completed enrollment for its Phase II clinical trial, targeting advanced non-small cell lung cancer; and HS-130, currently undergoing a Phase I clinical trial for advanced solid tumors. Additionally, PTX-35, a novel T-cell co-stimulator agonist antibody that specifically targets DR3/TNFRSF25, is also in Phase I development. The company is also exploring DR3/TNFRSF25 as a general target for various immunotherapy applications. Beyond these, a COVID-19 vaccine is currently in preclinical stages. A notable collaboration involves Dr. James Shapiro at the University of Alberta, focusing on the manufacturing of a surrogate mouse version of PTX-35. Originally established as Heat Biologics, Inc. in 2008, the company rebranded to NightHawk Biosciences, Inc. in May 2022. Its headquarters are located in Morrisville, North Carolina.
Share Price
$0.3136
Last synced: 2024-03-04
Market Cap
$7.97M
Change (1 day)
-3.00%
Change (1 year)
0.00%
Country
US
Trade NightHawk Biosciences, Inc. (NHWK)

Category

Healthcare
Operating Margin for NightHawk Biosciences, Inc. (NHWK)
Operating Margin as of 2026 TTM: 0.00%
According to NightHawk Biosciences, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for NightHawk Biosciences, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.